Skip to Content
Merck
  • Analyses of the pathways involved in early- and late-phase induction of IFN-beta during C. muridarum infection of oviduct epithelial cells.

Analyses of the pathways involved in early- and late-phase induction of IFN-beta during C. muridarum infection of oviduct epithelial cells.

PloS one (2015-03-24)
Sishun Hu, Kristen L Hosey, Wilbert A Derbigny
ABSTRACT

We previously reported that the IFN-β secreted by Chlamydia muridarum-infected murine oviduct epithelial cells (OE cells) was mostly dependent on the TLR3 signaling pathway. To further characterize the mechanisms of IFN-β synthesis during Chlamydia infection of OE cells in vitro, we utilized specific inhibitory drugs to clarify the roles of IRF3 and NF-κB on both early- and late-phase C. muridarum infections. Our results showed that the pathways involved in the early-phase of IFN-β production were distinct from that in the late-phase of IFN-β production. Disruption of IRF3 activation using an inhibitor of TBK-1 at early-phase Chlamydia infection had a significant impact on the overall synthesis of IFN-β; however, disruption of IRF3 activation at late times during infection had no effect. Interestingly, inhibition of NF-κB early during Chlamydia infection also had a negative effect on IFN-β production; however, its impact was not significant. Our data show that the transcription factor IRF7 was induced late during Chlamydia infection, which is indicative of a positive feedback mechanism of IFN-β synthesis late during infection. In contrast, IRF7 appears to play little or no role in the early synthesis of IFN-β during Chlamydia infection. Finally, we demonstrate that antibiotics that target chlamydial DNA replication are much more effective at reducing IFN-β synthesis during infection versus antibiotics that target chlamydial transcription. These results provide evidence that early- and late-phase IFN-β production have distinct signaling pathways in Chlamydia-infected OE cells, and suggest that Chlamydia DNA replication might provide a link to the currently unknown chlamydial PAMP for TLR3.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Sodium chloride, Molecular Biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Sodium chloride, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Sodium chloride, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Sodium dodecyl sulfate, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
Sodium dodecyl sulfate, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Sodium dodecyl sulfate, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Sodium chloride, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
Sodium chloride solution, BioUltra, Molecular Biology, ~5 M in H2O
Sigma-Aldrich
Sodium dodecyl sulfate, ≥98.0% (GC)
Sigma-Aldrich
Sodium dodecyl sulfate, BioUltra, Molecular Biology, ≥99.0% (GC)
Supelco
Sodium chloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium dodecyl sulfate, ACS reagent, ≥99.0%
Supelco
Sodium dodecyl sulfate, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, 20% in H2O
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
Ala-Gln, BioReagent, suitable for cell culture, suitable for insect cell culture
USP
Ofloxacin, United States Pharmacopeia (USP) Reference Standard
Sodium laurilsulfate, European Pharmacopoeia (EP) Reference Standard
Rifampicin, European Pharmacopoeia (EP) Reference Standard